Roche to complete $4.3 billion Spark deal as regulators give all clear
By Diane Bartz and John Miller
ZURICH/WASHINGTON (Reuters) - Swiss drugmaker Roche (NYSE: ROG) plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics (NASDAQ: ONCE) on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment.
The Federal Trade Commission (FTC) and Britain's Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales.
Roche is buying U.S.-based Spark to expand in gene therapy and boost its hemophilia A portfolio, where the Basel-based company's existing drug Hemlibra will surpass $1 billion sales in 2019.
Regulators had feared Roche might sabotage Spark's hemophilia program to benefit Hemlibra, but came to another conclusion.
"The evidence developed during staff's investigation did not indicate that Roche would have the incentive to delay or terminate Spark's developmental effort for its hemophilia A gene therapy," the FTC said after its 5-0 approval vote.
Clearance for Roche to buy Spark helps reduce the chance the Swiss drugmaker will be eclipsed in one of the industry's most dynamic and potentially profitable areas, as it was by Merck (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) in immune therapies for cancer.
"That's why the market was increasingly worried that the deal announced in February was taking so long," said Michael Nawrath, an analyst at Zuercher Kantonalbank.
The deal follows Novartis's (NASDAQ: NOVN) $8.7 billion takeover of gene therapy specialist AveXis in 2018.
Beyond hemophilia, Spark is also working on gene therapies for Pompe and Huntington's diseases, among others.
With the deal, Roche agreed to pay more than twice the U.S. company's closing price on Feb. 22. As of Tuesday, Roche held more than 60% of Spark shares.
"Following completion of the merger, Spark will become a wholly owned subsidiary of Roche," Roche said.
LUCRATIVE, COMPETITIVE
Hemophilia A, where sufferers lack a protein needed for blood clotting, has traditionally been one of the most expensive - and for companies, lucrative - treatment areas.
Traditional treatments can in some cases run into millions of dollars annually.
Spark's hemophilia A treatment is up against a crowded pool of gene therapy hopefuls, something the FTC said influenced its decision not to block the deal.
Biomarin Pharmaceutical (NASDAQ: BMRN) is seen filing for approval this year, while Sangamo Therapeutics Inc (NASDAQ: SGMO) and Pfizer Inc (NYSE: PFE) are steadily producing data from studies.
"As the other companies endeavor to bring their gene therapies to market, Roche would have the incentive to accelerate, rather than decelerate, the development of Spark’s gene therapy," the FTC said.
Roche stock eased 0.2% in early trading.
(Reporting by Diane Bartz; Editing by Sandra Maler, Sam Holmes, Chris Reese and Jan Harvey)